文献速递白血病

单体7/del(7q)导致急性髓系白血病对烟酰胺磷酸核糖转移酶抑制剂敏感

Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

研究分析114例原发急性髓系白血病(AML)样本的体外药物筛选数据,发现-7/-7q AML细胞对烟酰胺磷酸核糖转移酶(NAMPT)抑制高度敏感。机制为NAMPT基因位于7q22.3,-7/-7q导致单拷贝缺失引起NAMPT单倍剂量不足。BCL2抑制剂维奈克拉联合NAMPT抑制剂KPT-9274比单用NAMPT抑制剂导致-7/-7q AML样本中更多白血病原始细胞死亡。

要点

  • 114例原发AML样本体外药物筛选显示-7/-7q AML细胞对NAMPT抑制高度敏感。
  • NAMPT基因位于7q22.3,-7/-7q致单拷贝缺失引起NAMPT单倍剂量不足。
  • 维奈克拉联合KPT-9274较单用NAMPT抑制剂使-7/-7q AML样本中更多白血病原始细胞死亡。

核心结论

  • 伴-7/-7q的AML对NAMPT抑制高度敏感,提示NAMPT抑制剂有潜力成为单体7或del(7q)患者的有效靶向治疗。

研究设计与样本

  • 研究分析114例原发AML样本的体外药物筛选数据,以识别-7/-7q AML的新型治疗脆弱点。

主要发现

  • 在-7/-7q AML中,分化的CD34+CD38+髓系原始细胞较分化程度较低的CD34+CD38-髓系原始细胞对NAMPT抑制更敏感。
  • 在伴-7/-7q的AML样本中,BCL2抑制剂维奈克拉联合NAMPT抑制剂KPT-9274导致死亡的白血病原始细胞显著多于单用NAMPT抑制剂。
  • NAMPT基因位于7q22.3,-7/-7q导致1个拷贝缺失引起NAMPT单倍剂量不足,表达降低并形成可治疗靶向的NAMPT抑制脆弱性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monosomy 7 and del(7q) (-7/-7q) are frequent chromosomal abnormalities detected in up to 10% of patients with acute myeloid leukemia (AML). Despite unfavorable treatment outcomes, no approved targeted therapies exist for patients with -7/-7q. Therefore, we aimed to identify novel vulnerabilities. Through an analysis of data from ex vivo drug screens of 114 primary AML samples, we discovered that -7/-7q AML cells are highly sensitive to the inhibition of nicotinamide phosphoribosyltransferase (NAMPT). NAMPT is the rate-limiting enzyme in the nicotinamide adenine dinucleotide salvage pathway. Mechanistically, the NAMPT gene is located at 7q22.3, and deletion of 1 copy due to -7/-7q results in NAMPT haploinsufficiency, leading to reduced expression and a therapeutically targetable vulnerability to the inhibition of NAMPT. Our results show that in -7/-7q AML, differentiated CD34+CD38+ myeloblasts are more sensitive to the inhibition of NAMPT than less differentiated CD34+CD38- myeloblasts. Furthermore, the combination of the BCL2 inhibitor venetoclax and the NAMPT inhibitor KPT-9274 resulted in the death of significantly more leukemic blasts in AML samples with -7/-7q than the NAMPT inhibitor alone. In conclusion, our findings demonstrate that AML with -7/-7q is highly sensitive to NAMPT inhibition, suggesting that NAMPT inhibitors have the potential to be an effective targeted therapy for patients with monosomy 7 or del(7q).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Eldfors S, Saad J, Ikonen N, et al. Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia. Blood Adv. 2024. PMID: 38197948. doi:10.1182/bloodadvances.2023010435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。